ProteinQure Receives $2.5M Genome Canada Award to Advance siRNA Therapeutics for Glioblastoma

ProteinQure Inc., a clinical-stage biotechnology company leveraging machine learning and generative AI to design precision therapeutics, recently announced it has been awarded funding through the Genome Canada Genomic Applications Partnership Program (GAPP) to support preclinical testing of its lead candidates for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer.

ProteinQure is an OBIO® member, an alumnus of our BDSP™, CAAP®, HealthMINT® programs and Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence, and presented at the OBIO® Investment Summit.